Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMP360 phase III trial in treatment-resistant depression
NL-OMON59319Phase 3Active, not recruiting
- Sponsor
- COMPASS Pathways
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of COMP360 in treatment-resistant depression (TRD), sponsored by COMPASS Pathways. Primary endpoint: Change from baseline in MADRS total score at Week 6. Started Nov 2023; status: active, not recruiting.
02
Drugs
COMP360
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NL-OMON59319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59319.